

2012

## Chemotherapeutics for *vivax* malaria

J. Kevin Baird

*Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, jkevinbaird@yahoo.com*

Follow this and additional works at: <http://digitalcommons.unl.edu/publichealthresources>

---

Baird, J. Kevin, "Chemotherapeutics for *vivax* malaria" (2012). *Public Health Resources*. 345.  
<http://digitalcommons.unl.edu/publichealthresources/345>

This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

ORAL PRESENTATION

Open Access

# Chemotherapeutics for *vivax* malaria

J Kevin Baird

*From* Challenges in malaria research  
Basel, Switzerland. 10-12 October 2012

*Plasmodium vivax* imposes significant burdens of morbidity and mortality across the malaria endemic world. Treatment of this infection requires a blood schizonticide against the acute attack and hypnozoiticide against relapses. Chloroquine combined with primaquine has been the therapy of choice for radical cure of *vivax* malaria since the 1950s. Primaquine, however, was never optimized or adapted for use in endemic zones and its toxicity in prevalent G6PD-deficient patients (typically 5-20%) sharply limits its effectiveness. Resistance to chloroquine has emerged in Southeast Asia and now threatens the Indian sub-continent where most *P. vivax* occurs. The research community faces the steep challenge of developing new radical cure strategies. This presentation explores those challenges and the means to meet them, principally optimizing primaquine as a partner to new ACTs for maximum efficacy and more practical dosing and safety.

Published: 15 October 2012

doi:10.1186/1475-2875-11-S1-O21

**Cite this article as:** Baird: Chemotherapeutics for *vivax* malaria. *Malaria Journal* 2012 **11**(Suppl 1):O21.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia



© 2012 Baird; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.